There is a huge unmet need in the prediabetes market for
approved therapies since their effective treatment and management
can lead to the prevention of diabetes. There are no US
FDA-approved drugs available for the treatment of prediabetes.
Companies like Novo Nordisk (semaglutide) and Aphaia Pharma
(APH-012) are engaged in developing therapies for the treatment of
prediabetes.
LAS
VEGAS, June 19, 2024 /PRNewswire/ --
DelveInsight's Prediabetes Market Insights report
includes a comprehensive understanding of current treatment
practices, prediabetes emerging drugs, market share of individual
therapies, and current and forecasted market size from 2020 to
2034, segmented into 7MM [the United
States, the EU4 (Germany,
France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Prediabetes Market Report
- According to DelveInsight's analysis, the market size for
prediabetes is expected to grow significantly by 2034.
- As per DelveIsight assessment, 70.5% of prediabetes
cases are found in the 25–44 age group, while 40% and 51% of
diabetes cases are found in 25–44 and 45–60 aged individuals,
respectively.
- Leading prediabetes companies such as Novo Nordisk,
Aphaia Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company,
Corcept Therapeutics, and others are developing novel
prediabetes drugs that can be available in the prediabetes market
in the coming years.
- The promising prediabetes therapies in the pipeline include
Semaglutide, APH-012, HTD1801, Tirzepatide, and
Relacorilant, among others.
- In May 2024, Novo Nordisk
presented the Phase III trial (STEP 10) results of semaglutide in
subjects with obesity and prediabetes at the 31st European Congress
on Obesity (ECO). The results demonstrated that semaglutide 2.4 mg
provided a superior reduction vs placebo in body weight and
reversion to normoglycaemia in participants with obesity and
prediabetes.
Discover which therapies are expected to grab the major
prediabetes market share @ Prediabetes Market
Report
Prediabetes Overview
Prediabetes is a condition characterized by blood sugar levels
that are higher than normal but not yet high enough to be diagnosed
as type 2 diabetes. It serves as a critical warning sign and a
window of opportunity for individuals to take steps to prevent the
progression to diabetes. The primary causes of prediabetes include
insulin resistance, where the body's cells do not respond
effectively to insulin, and the pancreas's inability to produce
enough insulin to manage blood sugar levels. Risk factors for
developing prediabetes include being overweight, having a sedentary
lifestyle, poor dietary habits, a family history of diabetes, and
certain health conditions like hypertension and polycystic ovary
syndrome (PCOS).
Symptoms of prediabetes are often subtle or non-existent, making
it difficult for individuals to recognize the condition. However,
some people may experience signs such as increased thirst, frequent
urination, fatigue, and blurred vision. Despite the lack of
pronounced symptoms, it is crucial to diagnose prediabetes early
through appropriate testing. Diagnosis typically involves a fasting
plasma glucose test, an oral glucose tolerance test, or an HbA1c
test, which measures average blood sugar levels over the past two
to three months. Detecting prediabetes early allows for timely
lifestyle interventions, including weight loss, increased physical
activity, and dietary changes, which can significantly reduce the
risk of progressing to type 2 diabetes and improve overall
health.
Prediabetes Epidemiology Segmentation
The prediabetes epidemiology section provides insights into the
historical and current prediabetes patient pool and forecasted
trends for the 7MM. It helps recognize the causes of current and
forecasted patient trends by exploring numerous studies and views
of key opinion leaders.
The prediabetes market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Prevalent Cases of Prediabetes
- Total Diagnosed Prevalent Cases of Prediabetes
- Age-specific Cases of Prediabetes
- Gender-specific Cases of Prediabetes
- Treated Cases of Prediabetes
Prediabetes Treatment Market
In addition to adopting a healthy lifestyle, individuals with
prediabetes may benefit from various medications aimed at improving
insulin function and reducing Impaired Glucose Tolerance (IGT),
thereby hindering the progression to type 2 diabetes. Currently,
there are no specific treatments for prediabetes; however,
medications approved for T2D treatment, such as metformin,
thiazolidinediones, GLP-1 analogs, DPP-IV inhibitors, and
alpha-glucosidase inhibitors, are commonly utilized.
Metformin functions as an antihyperglycemic agent,
enhancing glucose tolerance in individuals with prediabetes or type
2 diabetes by reducing both baseline and after-meal blood sugar
levels. It's occasionally prescribed off-label. Metformin achieves
this by reducing liver glucose production, intestinal glucose
absorption, and by enhancing insulin sensitivity, promoting the
uptake and utilization of glucose in peripheral tissues. Another
class of medications used for managing these conditions includes
orally consumed GLP-1 analogs, which provoke a two- to
three-fold increase in plasma insulin response compared to
intravenous glucose-induced hyperglycemia. Commonly prescribed
GLP-1 receptor agonists such as liraglutide and exenatide are often
recommended for individuals with elevated insulin levels (insulin
resistance) or those on the brink of developing diabetes.
Subsequently, DPP-IV inhibitors like vildagliptin
act by binding covalently to the catalytic site of DPP-4, resulting
in prolonged enzyme inhibition. Lastly, alpha-glucosidase
inhibitors, known colloquially as starch blockers, are antidiabetic
agents that assist in lowering blood glucose levels after meals.
Unlike many other diabetes medications, they do not directly impact
insulin secretion or sensitivity. Instead, they work by slowing
down the breakdown of carbohydrates present in starchy foods.
Commonly prescribed alpha-glucosidase inhibitors for managing
prediabetes and T2D include acarbose, miglitol, voglibose,
among others.
To know more about prediabetes treatment guidelines, visit @
Prediabetes Management
Prediabetes Pipeline Therapies and Key Companies
The pipeline of prediabetes is not so robust and lacks essential
key players. Some of the emerging therapies include semaglutide
(Novo Nordisk), APH-012 (Aphaia Pharma), and others.
Novo Nordisk is exploring the effects of a 2.4 mg
subcutaneous injection of semaglutide in individuals with
obesity and prediabetes. This compound functions as a GLP-1
receptor agonist, operating through various mechanisms such as
increasing insulin secretion in response to glucose levels,
inhibiting glucagon release, and reducing hepatic gluconeogenesis.
These actions lead to a decrease in both fasting and postprandial
glucose levels.
In May 2024, Novo Nordisk released
findings from the Phase III trial (STEP 10) investigating
semaglutide in individuals with obesity and prediabetes. The trial
revealed that semaglutide 2.4 mg outperformed the placebo in
reducing body weight and returning subjects to normal blood sugar
levels, while also showing enhancements in cardiometabolic risk
factors.
Aphaia Pharma is currently assessing APH-012 in a
Phase II trial to determine its effectiveness in enhancing glucose
tolerance among individuals with prediabetes who exhibit abnormal
results in the Oral Glucose Tolerance Test (OGTT) after six weeks
of receiving APH-012.
Apart from these the other therapies in the pipeline for
prediabetes treatment include
- HTD1801: HighTide Biopharma Pty Ltd
- Tirzepatide: Eli Lilly and Company
- Relacorilant: Corcept Therapeutics
The anticipated launch of these emerging therapies for
prediabetes are poised to transform the market landscape in the
coming years. As these cutting-edge therapies continue to mature
and gain regulatory approval, they are expected to reshape the
prediabetes market landscape, offering new standards of care and
unlocking opportunities for medical innovation and economic
growth.
Discover more about prediabetes drugs in development @
Prediabetes Clinical Trials
Prediabetes Market Dynamics
The dynamics of the prediabetes market are expected to change in
the coming years. Increased public awareness, improved
access to health services, and rising obesity rates act
as market drivers, while T2D drugs, effective in treating
prediabetes, highlight an unmet need, as there is no approved
treatment for prediabetes, creating an opportunity for new
players and opening a platform for new therapies to boost the
market of the indication.
Furthermore, potential therapies are being investigated for the
treatment of prediabetes, and it is safe to predict that the
treatment space will significantly impact the
prediabetes market during the forecast period. Moreover, the
anticipated introduction of emerging therapies with improved
efficacy and a further improvement in the diagnosis rate are
expected to drive the growth of the prediabetes market in the
7MM.
However several factors may impede the growth of the prediabetes
market. Although awareness has improved from before, many patients
are still unaware that they have this condition, and lack
of a uniform classification/diagnostic criteria often leads to
confusion and misdiagnosis, potentially affecting the demand
for therapeutics as the disease could be controlled by a change in
lifestyle; furthermore, off-label usage might hamper the
uptake of novel therapies.
Moreover, prediabetes treatment poses a significant
economic burden and disrupts patients' overall well-being and
QOL. Furthermore, the prediabetes market growth may be offset
by failures and discontinuation of emerging therapies,
unaffordable pricing, market access and reimbursement
issues, and a shortage of healthcare specialists. In
addition, the undiagnosed, unreported cases and the
unawareness about the disease may also impact the
prediabetes market growth.
Prediabetes Market
Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Prediabetes
Companies
|
Novo Nordisk, Aphaia
Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company, Corcept
Therapeutics, and
others
|
Key Pipeline Prediabetes Therapies
|
Semaglutide, APH-012,
HTD1801, Tirzepatide, Relacorilant, and others
|
Scope of the Prediabetes Market
Report
- Therapeutic Assessment: Prediabetes current
marketed and emerging therapies
- Prediabetes Market Dynamics: Key Market
Forecast Assumptions of Emerging Prediabetes Drugs and Market
Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Prediabetes
Market Access and Reimbursement
Download the report to understand which factors are driving
prediabetes market trends @ Prediabetes Market
Trends
Table of Contents
1.
|
Prediabetes
Key Insights
|
2.
|
Prediabetes
Report Introduction
|
3.
|
Prediabetes Overview at
a Glance
|
4.
|
Prediabetes
Executive Summary
|
5
|
Prediabetes
Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Prediabetes
Treatment and Management
|
8.
|
Prediabetes
Guidelines
|
9.
|
Prediabetes
Epidemiology and Patient
Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Prediabetes
|
12.
|
Prediabetes Marketed
Drugs
|
13.
|
Prediabetes
Emerging Drugs
|
14.
|
7MM Prediabetes Market
Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Prediabetes Pipeline
Prediabetes Pipeline Insight – 2024 report provides
comprehensive insights about the pipeline landscape, pipeline drug
profiles, including clinical and non-clinical stage products, and
the key prediabetes companies, including Resverlogix
Corporation, Boston Therapeutics, vTv Therapeutics, Valbiotis,
BioTeSys, SynDevRx, Caelus Health, NanoPrecision Medical, among
others.
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market
Forecast – 2032 report deliver an in-depth understanding of the
disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key
diabetes companies, including Daewoong Pharmaceutical,
Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian,
Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen,
Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex
Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon
Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd
Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici
S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed
Pharmaceuticals, Janssen Research & Development, LLC, Jaguar
Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR
Therapeutics, Biora Therapeutics, Genprex, Inc., among
others.
Type 1 Diabetes Market
Type 1 Diabetes Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key type 1
diabetes companies, including Landos Biopharma, Zealand
Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals,
Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD
Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli
Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd
Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe
Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia,
Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma,
Jaguar Gene Therapy, SQZ Biotech, Enthera, among
others.
Type 2 Diabetes Market
Type 2 Diabetes Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key type 2
diabetes companies, including Eli Lilly and Company, Regor
Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind
Biosciences USA Co., Ltd.,
MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd,
Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis,
Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma,
Inversago Pharma Inc, Applied Therapeutics, Inc., among
others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/prediabetes-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2034-predicts-delveinsight--key-companies---novo-nordisk-aphaia-pharma-hightide-biopharma-pty-ltd-eli-lilly-and-company-corcept-therapeutics-302176480.html
SOURCE DelveInsight Business Research, LLP